BeOne Medicines (ONC) Non-Current Deferred Tax Liability (2016 - 2026)

BeOne Medicines (ONC) has reported Non-Current Deferred Tax Liability for 11 consecutive years, with $55.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 29.59% year-over-year to $55.9 million; the TTM figure through Mar 2026 stood at $55.9 million (up 29.59% YoY), while the FY2025 annual figure was $53.2 million, up 26.67% from the prior year.
• Non-Current Deferred Tax Liability grew to $55.9 million in Q1 2026 per ONC's latest filing, from $53.2 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $55.9 million in Q1 2026 and bottomed at $14.2 million in Q1 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $27.7 million across 5 years, with a median of $16.4 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability slipped 18.18% — and 2025, when it surged 195.36%.
• BeOne Medicines' Non-Current Deferred Tax Liability stood at $24.6 million in 2022, then declined by 18.18% to $20.1 million in 2023, then surged by 108.9% to $42.0 million in 2024, then grew by 26.67% to $53.2 million in 2025, then rose by 4.99% to $55.9 million in 2026.
• Business Quant data shows ONC's Non-Current Deferred Tax Liability at $55.9 million in Q1 2026, $53.2 million in Q4 2025, and $47.1 million in Q3 2025.